<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01747096</url>
  </required_header>
  <id_info>
    <org_study_id>BRD/11/05-K</org_study_id>
    <nct_id>NCT01747096</nct_id>
  </id_info>
  <brief_title>TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors</brief_title>
  <acronym>68-DOTANOC-GEP</acronym>
  <official_title>Diagnostic, Prospective, Comparative, Multicentric Study of the PET / CT With 68Ga-DOTANOC Versus Conventional Imaging Procedures (octréoscan ® Scintigraphy and CT / MRI) in the Assessment of in Gastroenteropancreatic Neuroendocrine Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the diagnostic performance of PET / CT with 68Ga-DOTANOC in&#xD;
      Gastroenteropancreatic Neuroendocrine Tumors with comparison with other techniques used in&#xD;
      routine clinical practice (octreoscan ® ; multiphase SPECT / CT, MRI or endoscopy).&#xD;
&#xD;
      Therapeutic impact and safety of PET / CT with 68Ga-DOTANOC will also be assessed. Expected&#xD;
      results are a confirmation of the superiority of 68Ga-PET DOTANOC versus scintigraphy&#xD;
      octreoscan ®, with a potential impact on the therapeutic management of patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of Gastroenteropancreatic Neuroendocrine Tumors lesions in the initial assessment or during the search of recurrence.</measure>
    <time_frame>12 months</time_frame>
    <description>Reference to the gold standard (that will be obtained from the data of histology and / or follow-up imaging at least 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the diagnostic performance of PET / CT with 68Ga-DOTANOC with the standard process</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Assess the clinical impact of PET / CT 68 Ga-DOTANOC in terms of specificity and predictive value for the detection of locations of GEP.</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Assess the relevance of decisions of PET / CT 68 Ga-DOTANOC in terms of specificity and predictive value for the detection of locations of GEP.</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Assess the value of PET / CT 68 Ga-DOTANOC in terms of specificity and predictive value for the detection of locations of GEP.</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Tolerance of 68-Ga-DOTANOC</measure>
    <time_frame>12 mois</time_frame>
    <description>the vital signs and clinical tolerance will be assess during the 2 hours following injection of the radiopharmaceutical.</description>
  </other_outcome>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Patients With Gastroenteropancreatic Neuroendocrine Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68-Ga-DOTANOC</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age over 18 years&#xD;
&#xD;
          -  effective contraception or exclusion of pregnancy dosage of beta-HCG in women of&#xD;
             childbearing age&#xD;
&#xD;
          -  Fortuitous discovery of suggestive tumors of TE-GEP with well documented conventional&#xD;
             imaging (multiphase CT; MRI, US endoscopy) associated or not associated with clinical&#xD;
             or biological signs of TE-GEP tumors (increase in tumor markers) OR&#xD;
&#xD;
          -  Histologically proven GEP-TE (WHO classification 2010 (26) well differentiated in the&#xD;
             initial staging OR&#xD;
&#xD;
          -  Suspicion of recurrence or progression of well differentiated TE-GEP tumors on&#xD;
             conventional imaging or laboratory tests (increase in tumor markers) OR&#xD;
&#xD;
          -  Clinical or biological syndrome strongly suggestive of digestive endocrine disease&#xD;
             without identification of lesions with conventional imaging&#xD;
&#xD;
          -  Informed consent and patient's written&#xD;
&#xD;
          -  Affiliation to an insurance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Multiple endocrine neoplasia&#xD;
&#xD;
          -  TE GEP tumor not differentiated&#xD;
&#xD;
          -  Pregnancy and lactation&#xD;
&#xD;
          -  Persons protected by law&#xD;
&#xD;
          -  Restlessness, inability to lie still hold at least 1 hour; Claustrophobia&#xD;
&#xD;
          -  Poor compliance predictable or inability to undergo medical test for geographical,&#xD;
             social or psychological&#xD;
&#xD;
          -  Treatment with radiotherapy, chemotherapy or other antitumor treatment within 6 weeks&#xD;
             of previous morphological and scintigraphic examinations. In case of treatment with&#xD;
             somatostatin analogues delayed, scans will be performed 4 weeks after the last&#xD;
             injection. However, a shorter period may be observed to avoid to do again the initial&#xD;
             assessment exams.&#xD;
&#xD;
          -  malignancy except basal cell cancers and cancer in situ of the cervix&#xD;
&#xD;
          -  Contraindication of injection of a contrast agent necessary for the production of&#xD;
             multiphase scanner.&#xD;
&#xD;
          -  Patients who had a CT scan without injection of contrast material can not participate&#xD;
             in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Ansquer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Angers Hospital</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest, René Gauducheau</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nantes Hospital</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>November 13, 2012</study_first_submitted>
  <study_first_submitted_qc>December 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2012</study_first_posted>
  <last_update_submitted>July 28, 2016</last_update_submitted>
  <last_update_submitted_qc>July 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastroenteropancreatic Neuroendocrine Tumors</keyword>
  <keyword>immuno PET (iPET)</keyword>
  <keyword>Gallium (68-Ga)</keyword>
  <keyword>DOTANOC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

